<DOC>
	<DOCNO>NCT00889850</DOCNO>
	<brief_summary>The present study conduct order compare bioavailability 40 mg Esomeprazole Mepha ( Mepha Ltd. , Switzerland ) INexium 40 mg MUPS tablet ( AstraZeneca , France ) single dose fast fed condition . The study conduct combined single dose study fast fed condition 2x2-period cross-over design wash phase least 6 treatment-free day administration .</brief_summary>
	<brief_title>Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted Fed Administration</brief_title>
	<detailed_description>- The primary objective single dose fast part study compare rate extent absorption esomeprazole 40 mg Esomeprazole Mepha capsule ( Test ) 40 mg Esomeprazole INexium MUPS tablet ( Reference ) single dose administration fast condition , determine use AUC0-tlast Cmax obtain esomeprazole plasma concentration . - The primary objective single dose feed combination fast part study compare maximum concentration esomeprazole determine 40 mg Esomeprazole Mepha capsule ( Test ) single dose administration feed condition comparison 40 mg Esomeprazole INexium MUPS tablet ( Reference ) single dose administration fast fed condition .</detailed_description>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Subject : 1. Caucasian male 2. aged 1855 year , inclusive 3. bodymass index ( BMI ) : ≥ 19 kg/m² ≤ 27 kg/m² 4. consider healthy basis extensive prestudy eligibility assessment 5. nonsmoker exsmoker least 1 month 6. willing capable confirm write consent enrolment ample information provide Subjects include match follow exclusion criterion : 1. existence surgical medical condition might interfere absorption , distribution , metabolism excretion drug , i.e . impaired renal hepatic function , diabetes mellitus , cardiovascular abnormality , chronic symptom pronounce constipation diarrhoea condition associate total partial obstruction urinary tract . 2. presence active gastric/duodenal ulcer gastrointestinal bleeding , enteritis like Crohn 's disease ulcerative colitis , clinically confirm coronary heart disease and/or cerebrovascular disease , cardiac insufficiency ( NYHA IIIV ) , severe liver insufficiency , severe renal insufficiency 3. history relevant CNS and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 4. pathological ECG ( 12 standard lead ) 5. know allergic reaction active ingredient use , substitute benzimidazole constituent pharmaceutical preparation 6. subject severe allergy multiple drug allergy 7. positive result urine drug screen 8. laboratory value normal range unless deviation normal judge relevant study investigator 9. positive antiHIVtest , HBsAGtest antiHCVtest 10. lactose fructose intolerance 11. glucosegalactose malabsorption 12. history current drug alcohol dependence 13. regular intake alcoholic food beverage ≥ 40 g pure ethanol per day 14. subject diet could affect pharmacokinetics drug 15. regular intake caffeine contain food beverage ≥ 500 mg caffeine per day 16. blood donation blood loss 400 ml within last two month prior start study 17. participation clinical trial last two month prior start study 18. subject , report frequent occurrence migraine attack 19. regular treatment systemically available medication ( except hormonal replacement therapy e.g . Lthyroxine ) within 14 day prior first administration study medication 20. subject suspect know follow instruction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Esomeprazole</keyword>
	<keyword>Bioavailability , Therapeutical Indication Not Studied</keyword>
</DOC>